Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Pharma News, Views & Analysis
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
Spotlight: May 2025
Catch up on May’s key pharma news, research updates and policy shifts.
Read more
BMS names Cari Gallman as new General Counsel
Gallman takes on the role of EVP, General Counsel and Chief Policy Officer, following Sandra Leung’s retirement after 33 years.
Spotlight: April 2025
From new scientific data-sharing initiatives to US drug tariffs, May brought a range of major news to the pharma landscape.
Lilly partners with Alchemab for ALS candidate
Eli Lilly joins forces with Alchemab in a deal worth $415m, expanding its neuroscience pipeline with a novel candidate.
US unveils new universal vaccine platform
Generation Gold Standard is a universal vaccine platform targeting influenza, coronaviruses and future pandemics.
Novartis acquires Regulus Therapeutics and potential first-in-class therapeutic
Novartis announces acquisition of Regulus Therapeutics, adding a potential first-in-class miR-17 inhibitor to its renal pipeline.
ViiV, Roche and Gilead lead pharma patient group rankings
ViiV leads the 2024/25 pharma company reputation rankings, with the PatientView report also finding ways to improve.
Ireland launches landmark childhood cancer genomics study
Ireland has launched its first national clinical genomics study in paediatric oncology.
Boehringer and Tessellate partner to tackle tough cancer targets
Boehringer Ingelheim and Tessellate Bio form a €500m partnership to develop precision therapies.
US pharma tariffs: What they mean for drug prices
US drug tariffs may not hit branded prices hard, but generics and supply chains face disruption. Here’s what pharma leaders need to know.
Scientists crack the code for keeping lab-grown tissue alive
FluidForm Bio’s 3D bioprinting tech keeps lab-grown cells alive five times deeper using vascular-like gelatin scaffolds.
UK enacts new clinical trial regulations
The UK government has formally signed into law new clinical trial regulations, designed to modernise operations across the country.
New tool supercharges lipid nanoparticle analysis
CloudSpec speeds up lipid nanoparticle analysis, cutting lab times from hours to seconds for gene therapy and vaccine research.
UK government unveils Health Data Research Service
The UK government has announced a significant new initiative to accelerate drug discovery and improve patient care in the country.
Pharma must balance creativity and trust in 2025, says VML
Pharma must balance creativity with transparency to rebuild trust in 2025. VML Health’s report reveals key trends shaping expectations.
Novo Nordisk announces significant leadership reshuffle
Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an expanded role.
Spotlight: March 2025
From the latest news impacting the UK’s NHS to large industry acquisitions, March brought a range of impactful news.
Spoonful of technology: Jan-March 2025
Discover the latest pharma innovations, from needle-free vaccines to NHS data access and interactive case studies in medical education.
Could gene therapy transform heart failure treatment?
A gene therapy for heart failure with preserved ejection fraction (HFpEF) has shown promising early results.
Sanofi's chlamydia vaccine fast-tracked by FDA
This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.
New study shines light on dementia in the workplace
A new study is challenging the belief that dementia is incompatible with modern work environments, with AI helping employees stay in work.
Pharma’s innovation ROI: Gains made, challenges ahead
The biopharmaceutical industry’s return on investment in innovation is increasing, but R&D costs are rising, according to a new Deloitte report.
VPAG hikes put UK life sciences at risk, warns pharma
The industry already contributes more than £17.6 billion directly to the UK economy, but it believes that growth has stagnated because of VPAG.
Pfizer completes exit from Haleon
Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.
AstraZeneca buys EsoBiotec in $1bn cell therapy deal
AstraZeneca has announced a $1bn agreement to acquire EsoBiotec, a Belgian biotech firm pioneering in vivo cell therapies.
Loading posts...
« Previous
1
2
3
4
5
6
…
28
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View